Nevro (NVRO)

Executive Summary

Nevro is a commercial-stage medical device company specializing in spinal cord stimulation (SCS) for chronic pain management. Its flagship HFX platform delivers 10 kHz Therapy and other waveforms, offering patients a non-pharmacological option for pain relief. The company has built a strong clinical evidence base and a direct sales force in the U.S., targeting the large and growing chronic pain market. Despite facing competition from established players like Medtronic, Abbott, and Boston Scientific, Nevro differentiates itself through proprietary high-frequency therapy and comprehensive patient support services. The company's focus on innovation and outcomes data positions it well to capture market share, particularly as opioid alternatives gain traction. Financially, Nevro has generated steady revenue growth but remains unprofitable as it invests in sales expansion and R&D. The company's recent launch of the HFX™ iQ™, an AI-driven SCS system, represents a key advancement that could differentiate its offering and drive adoption. However, reimbursement headwinds and market penetration challenges persist. Near-term catalysts include potential FDA label expansions, clinical trial readouts for new indications (e.g., non-surgical back pain), and international market expansion. With a strong balance sheet and a focused strategy, Nevro is positioned to navigate the competitive landscape and deliver long-term value for shareholders.

Upcoming Catalysts (preview)

• Q2 2026FDA approval of 10 kHz therapy for non-surgical back pain70% success
• Q3 2026Positive pivotal trial results for HFX iQ in treating painful diabetic neuropathy80% success
• Q4 2026Japan Ministry of Health approval for SCS system60% success